Prognosis
Pfizer, U.S. Wrangle Over Vaccine Pace While Working Toward Pact
- Drugmaker says no issues with output after governors complain
- Slaoui says deal for another 100 million doses of shot is near
This article is for subscribers only.
Pfizer Inc. pushed back on claims it is experiencing problems producing its Covid-19 vaccine, as the company and the federal government continued to try to reach a deal that would eventually double the number of doses available for the U.S.’s vast immunization effort.
Moncef Slaoui, the chief scientific adviser to Operation Warp Speed, said in an interview on Thursday that the U.S. is close to a deal for another 100 million doses of the vaccine Pfizer developed in partnership with BioNTech SE. Through the agreement, Pfizer would deliver the additional supply in the second quarter of 2021, Slaoui said.